TrialBlood2024

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.

Sasanka M Handunnetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.